Advertisement

Metformin and lipodystrophy

NEW YORK, 26 July (Praxis Press) The human immunodeficiency virus (HIV) lipodystrophy syndrome is characterized by fat redistribution and insulin resistance; this syndrome is particularly common among patients receiving combined antiretroviral therapy. Hadigan and colleagues studied the safety and efficacy of metformin in patients with the HIV lipodystrophy syndrome. Low-dose metformin treatment decreased body mass index and abdominal fat, improved hyperinsulinemia, and lowered diastolic blood p

July 27, 2000

NEW YORK, 26 July (Praxis Press) The human immunodeficiency virus (HIV) lipodystrophy syndrome is characterized by fat redistribution and insulin resistance; this syndrome is particularly common among patients receiving combined antiretroviral therapy. Hadigan and colleagues studied the safety and efficacy of metformin in patients with the HIV lipodystrophy syndrome. Low-dose metformin treatment decreased body mass index and abdominal fat, improved hyperinsulinemia, and lowered diastolic blood pressure. No serious adverse effects were noted; mild diarrhea was the most common minor adverse effect. Low-dose metformin is an effective and well-tolerated treatment for HIV lipodystrophy.

Advertisement

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
R&D Systems
R&D Systems
Advertisement
Life Technologies